The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations. For more information, please visit the Company's website at ...

The Company has also developed a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations. For more information, please visit the Company's website at ...

In June 2023, POINT Biopharma and AdvanCell collaborated on developing a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network for 212Pb-labeled radioligands by ...

The poster presentation entitled "Interim Safety and Efficacy data of [212Pb]VMT-α-NET in Somatostatin Receptor 2 (SSTR2) Expressing Neuroendocrine Tumors (NETs)” will be presented as a part of ...

In June 2023, POINT Biopharma and AdvanCell collaborated on developing a global 212Pb radioisotope and radioligand supply chain and drug manufacturing network for 212Pb-labeled radioligands by each ...

Perspective Therapeutics reports no dose-limiting toxicities or severe adverse events in Phase 1/2a trial of [212Pb]VMT-α-NET. Anti-tumor activity observed: 1 confirmed response (17 weeks), 2 ...

Find out more about how we test. With the NordPass password generator, you can quickly create new passwords both online and within the NordPass password management app. It supports the generation ...

Presenting on behalf of Molecular Partners will be Michael Stumpp, Ph.D., Execut MP0712, a 212Pb-Radio-DARPin targeting DLL3, as first candidate of Molecular Partners’ RDT platform in ...

Delhi, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Global Targeted Alpha Therapy Market Size, Drugs Approval, Proprietary Technologies and Clinical Trials Insight 2028 Report Highlights: Global Targeted Alpha ...